Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Maintenance in AL Amyloidosis
NCT03618537Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in amyloid light chain amyloidosis, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2018; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT03618537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618537.